- Biomarker 01
- ApoB
- Biomarker 02
- LDL Cholesterol
Quick answer.
ApoB counts atherogenic particles; LDL-C measures cholesterol mass. ApoB is superior for predicting heart disease because each particle carries one ApoB protein. Target ApoB under 80 mg/dL (under 60 for high risk). LDL-C can miss risk when particles are small and dense.
Key differences.
- What it measures — ApoB: Number of atherogenic particles; LDL-C: Cholesterol mass in LDL particles.
- Captures all atherogenic lipoproteins — ApoB: Yes - LDL, VLDL, IDL, Lp(a); LDL-C: No - only LDL particles.
- Affected by particle size — ApoB: No - counts particles regardless of size; LDL-C: Yes - misses risk with small dense LDL.
- Fasting required — ApoB: No; LDL-C: Traditionally yes, now often non-fasting.
When to use each.
ApoB
- Comprehensive cardiovascular risk assessment
- Patients with metabolic syndrome
- Discordance between LDL-C and triglycerides
- Monitoring aggressive lipid therapy
LDL Cholesterol
- Initial cardiovascular screening
- Monitoring statin response
- When ApoB is unavailable
- General population screening
Use both
- Detecting LDL-ApoB discordance
- High-risk patients (family history, diabetes)
- Longevity-focused protocols
- When optimizing beyond guidelines
Side-by-side.
| Feature | ApoB | LDL-C |
|---|---|---|
| What it measures | Atherogenic particle count | Cholesterol in LDL particles |
| Optimal for longevity | < 80 mg/dL | < 100 mg/dL |
| Aggressive target | < 60 mg/dL | < 70 mg/dL |
| Guideline inclusion | Growing but not universal | Standard of care |
| Availability | Specialty/request | Standard lipid panel |
| Cost | ~$30-75 | Included in lipid panel |
FAQs.
Why is ApoB better than LDL-C for predicting heart disease?
Atherosclerosis is driven by particle number, not cholesterol mass. Each atherogenic particle carries one ApoB protein, making ApoB a direct particle count. Two people with identical LDL-C can have vastly different particle counts if one has small dense LDL. ApoB captures this difference.
When do LDL-C and ApoB disagree?
Discordance is common with metabolic syndrome, diabetes, obesity, and high triglycerides. These conditions promote small dense LDL particles. You can have 'normal' LDL-C but elevated ApoB (more particles carrying less cholesterol each) - this is high risk that LDL-C misses.
Should everyone get ApoB tested?
For longevity optimization, yes. ApoB provides superior risk assessment. However, for basic screening, LDL-C remains appropriate. Prioritize ApoB if you have metabolic syndrome, family history, or are optimizing beyond guidelines.
What lowers ApoB effectively?
Statins are most effective, reducing ApoB 40-50%. PCSK9 inhibitors add another 50-60% reduction. Ezetimibe adds 15-20%. Lifestyle changes (weight loss, reduced refined carbs) help modestly. Niacin is less effective for ApoB than LDL-C.
Verdict.
ApoB is the superior cardiovascular risk marker. It counts all atherogenic particles and doesn't miss risk from small dense LDL. For longevity optimization, target ApoB under 80 mg/dL (under 60 if aggressive). LDL-C remains useful for monitoring and when ApoB is unavailable, but treat discordance seriously - trust ApoB over LDL-C when they disagree.